Digestive System Neoplasms Clinical Trial
Official title:
Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer: a Randomized, Multicenter, Controlled Pilot Study (EmoVie-K2)
Emotional skills are the ability to use emotions cleverly in daily life. Good emotional skills are associated with better mental and physical health in healthy and clinical populations. However, to our knowledge, cancer patients have never benefited from an intervention aiming at increasing their emotional skills. Our goal was thus to design and test such an intervention. A prospective, multi-center, randomized controlled trial (RCT) will be conducted in esogastric and lung cancer patients after antineoplastic treatments. Forty-three patients are expected in each arm. The primary outcome is the change in emotional skills assessed using a patient-reported validated questionnaire between the start and two weeks after the end of the intervention and at 2-month follow-up. The experimental arm will have to follow three individual sessions on emotional skills (i.e. identification, understanding, expression and regulation of emotions) while the control arm will have to follow three sessions of relaxation. In each arm, the first session can be held face to face or over the phone and the last two sessions will be held over the phone. Patients have exercises to practice in between sessions.It is hypothesised that the experimental group will experience a greater increase in emotional skills than the control group.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06026800 -
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms
|
Phase 1 | |
Recruiting |
NCT06026774 -
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms
|
Phase 1 | |
Recruiting |
NCT06019702 -
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms
|
Phase 1 | |
Completed |
NCT02909452 -
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT05602935 -
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
|
Phase 2 | |
Recruiting |
NCT04518852 -
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
|
Phase 2 | |
Completed |
NCT03717298 -
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05322486 -
Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
|
||
Terminated |
NCT03306693 -
Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers
|
N/A | |
Active, not recruiting |
NCT01037049 -
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
|
Phase 2 | |
Recruiting |
NCT02208804 -
Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization
|
Phase 2/Phase 3 | |
Completed |
NCT04080843 -
Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
|
Phase 2 | |
Recruiting |
NCT03303495 -
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
|
Phase 3 | |
Terminated |
NCT04644315 -
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03271255 -
Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)
|
Phase 2 | |
Recruiting |
NCT03221335 -
EUS-guided RFA for Solid Abdominal Neoplasms
|
N/A | |
Recruiting |
NCT02487017 -
DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT01556815 -
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
|
Phase 2 | |
Recruiting |
NCT04949282 -
Spanish Series of Patients Treated With the Radionuclide Lutetium177
|
||
Completed |
NCT01964430 -
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
|
Phase 3 |